ELEVATE Studies
The ELEVATE Studies are clinical research studies looking at rodatristat ethyl as a potential treatment for adults diagnosed with Pulmonary Arterial Hypertension (PAH).
ELEVATE 2 Study
The ELEVATE 2 Study aimed to help researchers understand if rodatristat ethyl, an investigative oral medicine, is safe and effective when used with a patient’s usual medicines for the treatment of their PAH. The ELEVATE 2 Study is no longer enrolling patients. For physicians and others who would like more details about the ELEVATE 2 Study, please visit www.ClinicalTrials.gov. Check back for updates.
Rodatristat Ethyl
Rodatristat ethyl, the ELEVATE Studies medicine, has the potential to be a new way to treat PAH. Given by mouth as a tablet, rodatristat ethyl uses a process called tryptophan hydroxylase (TPH) inhibition to reduce the amount of serotonin in the body.
Why focus on reducing serotonin? Research has shown that increased levels of serotonin in the body can play a role in the development of PAH.
Serotonin is a substance that occurs naturally in your body. It is mainly found in your brain and digestive tract and appears to affect and/or control a number of body functions. It is thought that too much serotonin in the body may cause arteries in the lungs to narrow.
Doctors hope the ELEVATE Studies medicine, rodatristat
ethyl, can reduce the
amount of serotonin affecting the lung arteries, which may open the arteries to
allow blood to flow more easily.
Healthy artery
Artery of person with PAH
Study Sponsor
The ELEVATE Studies are sponsored by Altavant Sciences GmbH (Altavant), a clinical stage biopharmaceutical company formed to advance promising therapies that treat rare respiratory diseases with an initial therapeutic focus on PAH.